Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $250.00 Price Target at Morgan Stanley

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective upped by Morgan Stanley from $164.00 to $250.00 in a research note published on Tuesday morning, Benzinga reports. Morgan Stanley currently has an equal weight rating on the biopharmaceutical company’s stock.

Several other research firms have also commented on ALNY. Needham & Company LLC increased their target price on shares of Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the company a buy rating in a research note on Monday, June 24th. Canaccord Genuity Group reissued a buy rating and set a $283.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, June 21st. StockNews.com raised Alnylam Pharmaceuticals from a hold rating to a buy rating in a research report on Monday, April 29th. BMO Capital Markets reiterated an outperform rating and issued a $234.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Finally, William Blair reissued an outperform rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Eight analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $247.09.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $243.00 on Tuesday. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $252.87. The stock has a fifty day moving average price of $159.86 and a two-hundred day moving average price of $164.73. The firm has a market cap of $30.74 billion, a P/E ratio of -90.67 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. During the same period in the previous year, the firm earned ($1.40) earnings per share. Alnylam Pharmaceuticals’s revenue was up 54.8% on a year-over-year basis. On average, research analysts predict that Alnylam Pharmaceuticals will post -3.75 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the transaction, the director now directly owns 136 shares of the company’s stock, valued at $30,013.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the completion of the sale, the director now owns 136 shares of the company’s stock, valued at $30,013.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the transaction, the director now directly owns 8,436 shares in the company, valued at approximately $1,253,589.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 67,357 shares of company stock valued at $13,436,711. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. ANTIPODES PARTNERS Ltd grew its holdings in Alnylam Pharmaceuticals by 69.1% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock valued at $36,203,000 after buying an additional 77,307 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after acquiring an additional 287,064 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its position in Alnylam Pharmaceuticals by 155.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 12,513 shares during the period. Westpac Banking Corp raised its stake in Alnylam Pharmaceuticals by 59.8% during the 4th quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 566 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Alnylam Pharmaceuticals by 630.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,160 shares of the biopharmaceutical company’s stock valued at $5,007,000 after purchasing an additional 22,580 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.